CIK: 0001704132 · Show all filings
Period: Q3 2020 (← Previous) (Next →)
Filing Date: Nov 13, 2020
Total Value ($000): $443,450 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | 2,139,380 | $91,116 | 20.5% | $38.13 | 0.0% | COM | 75943R102 |
| NRIX | Nurix Therapeutics, Inc. | 2,348,014 | $81,969 | 18.5% | $25.20 | 0.0% | COM | 67080M103 |
| KROS | Keros Therapeutics, Inc. | 1,412,705 | $54,488 | 12.3% | $30.81 | +28.7% | COM | 492327101 |
| KURA | Kura Oncology, Inc. | 1,307,982 | $40,077 | 9.0% | $14.39 | +53.4% | COM | 50127T109 |
| ALXO | ALX Oncology Holdings Inc. | 973,514 | $36,740 | 8.3% | $39.31 | 0.0% | COM | 00166B105 |
| CYTK | Cytokinetics Incorporated | 1,672,292 | $36,205 | 8.2% | $8.72 | +168.2% | COM | 23282W605 |
| — | Generation Bio Co. | 857,939 | $26,519 | 6.0% | $21.00 | — | COM | 37148K100 |
| PCVX | Vaxcyte, Inc. | 465,821 | $23,002 | 5.2% | $32.16 | +23.8% | COM | 92243G108 |
| — | Myokardia, Inc. | 126,492 | $17,245 | 3.9% | $47.61 | — | COM | 62857M105 |
| — | Cymabay Therapeutics, Inc. | 1,787,094 | $12,939 | 2.9% | $3.49 | — | COM | 23257D103 |
| ABUS | Arbutus Biopharma Corp | 3,332,616 | $10,431 | 2.4% | $3.04 | 0.0% | COM | 03879J100 |
| VYGR | Voyager Therapeutics, Inc. | 516,751 | $5,514 | 1.2% | $21.95 | — | COM | 92915B106 |
| — | Therapeutics Acquisition Corp | 350,000 | $5,033 | 1.1% | $14.38 | — | COM CL A | 88339T103 |
| — | Panacea Acquisition Corp | 150,000 | $1,800 | 0.4% | $12.00 | — | UNIT | 698102209 |
| ACRS | Aclaris Therapeutics, Inc. | 144,874 | $372 | 0.1% | $2.24 | 0.0% | COM | 00461U105 |